Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Pacific Biosciences Gained as Much as 10.5% Today

By Maxx Chatsko - Nov 20, 2019 at 11:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Illumina just proposed the nuclear option to earn regulatory approval for its merger and keep its biggest competitor at bay.

What happened

Shares of Pacific Biosciences ( PACB -1.77% ) rose over 10% today after the latest regulatory development injected optimism into investors hoping that the proposed merger with Illumina ( ILMN 0.07% ) will pass muster in the United Kingdom. 

In an effort to appease regulators critical of the merger, Illumina has offered to provide royalty-free licenses to all intellectual property in single-molecule, native long-read DNA sequencing owned by Illumina and Pacific Biosciences at the time of the merger closing and to any patents granted up to 12 months after closing. 

As of 10:55 a.m. EST, the small-cap stock had settled to a 8.1% gain. Shares of Illumina had settled to a gain of 1.3%.

A businessman sitting at a table looking through large binoculars.

Image source: Getty Images.

So what

The primary reason for Illumina to acquire Pacific Biosciences is that the latter has the leading long-read, single-molecule DNA sequencing technology platform. It can read parts of the human genome that Illumina's short-read approach cannot see, which has made it increasingly valuable to researchers asking difficult questions about genetic links to disease. 

Therefore, it may seem odd that Illumina would open up the IP at the center of the merger, but there's a not-so-subtle power play here. 

The United Kingdom's Competition and Markets Authority (CMA) has taken a critical stance on the proposed merger, citing the massive market share the merged company would hold in the global DNA sequencing market. It's right. But the U.K. is also home to Oxford Nanopore, which is developing a technology platform based on nanopore sequencing that could eventually overtake both Illumina and Pacific Biosciences. In other words, the CMA is partially protecting its homegrown sequencing powerhouse.

By proposing to open up all intellectual property related to single-molecule, native long-read DNA sequencing, Illumina is essentially making two bets. First, Illumina thinks it can commercialize and improve the existing technology of Pacific Biosciences better than any competitor. It currently dominates the global DNA sequencing market in terms of reach and customer relationships, so that's not a stretch.

Second, the move is an attempt to call CMA's bluff over arguments that market competition would suffer from the merger. If Roche and Agilent and every other competitor has access to the technology, that should increase competition in DNA sequencing. More subtly, the move would change the battle for the future of sequencing from Oxford Nanopore vs. Illumina to Oxford Nanopore vs. an all-star billing along the lines of Illumina, Roche (which is developing its own nanopore sequencing platform), Agilent, and everyone else. 

Now what

There's no guarantee that the latest proposal from Illumina will be enough to appease U.K. regulators, which can block the merger regardless of the decisions handed down by trade authorities in other countries (and even the broader European Union). In the long run, the recommendation from the CMA may not matter that much if nanopore sequencing can live up to its potential for faster, more accurate, and scaled-down DNA sequencing. 

Considering shares of Pacific Biosciences are trading well below the proposed acquisition price of $8 per share, investors can see there's a long way to go before the public markets take Illumina's proposal seriously. What happens heading into an important regulatory deadline on December 11 may determine how this ends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$365.57 (0.07%) $0.24
Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$22.80 (-1.77%) $0.41
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$49.81 (2.11%) $1.03
Agilent Technologies, Inc. Stock Quote
Agilent Technologies, Inc.
A
$152.02 (0.74%) $1.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.